Marieke van Son

118 CHAPTER 6 REFERENCES 1. Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global In- cidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur Urol. 2016;70(5):862-74. 2. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol. 2015;67(6):1009-16. 3. Tran H, Kwok J, Pickles T, Tyldesley S, Black PC. Underutilization of local salvage therapy after radiation ther- apy for prostate cancer. Urol Oncol. 2014;32(5):701-6. 4. Nguyen PL, Alibhai SM, Basaria S, D’Am- ico AV, Kantoff PW, Keating NL, et al. Ad- verse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825-36. 5. Golbari NM, Katz AE. Salvage Thera- py Options for Local Prostate Cancer Recurrence After Primary Radiothera- py: a Literature Review. Curr Urol Rep. 2017;18(8):63. 6. Philippou Y, Parker RA, Volanis D, Gnanapragasam VJ. Comparative On- cologic and Toxicity Outcomes of Sal- vage Radical Prostatectomy Versus Nonsurgical Therapies for Radiorecur- rent Prostate Cancer: A Meta-Regres- sion Analysis. European urology focus. 2016;2(2):158-71. 7. Lindenberg ML, Turkbey B, Mena E, Choyke PL. Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review. JAMA oncology. 2017;3(10):1415-22. 8. Patel P, Mathew MS, Trilisky I, Oto A. Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer. Radiographics : a review pub- lication of the Radiological Society of North America, Inc. 2018;38(2):437-49. 9. Duijzentkunst DA, Peters M, van der Voort van Zyp JR, Moerland MA, van Vulpen M. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehen- sive review. World journal of urology. 2016;34(11):1521-31. 10. Khoo CC, Miah S, Connor MJ, Tam J, Winkler M, Ahmed HU, et al. A system- atic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer. Translational andrology and urology. 2020;9(3):1535-45. 11. van Andel G, Bottomley A, Fossa SD, Effi- cace F, Coens C, Guerif S, et al. An inter- national field study of the EORTC QLQ- PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. European journal of cancer. 2008;44(16):2418-24. 12. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. Journal of clinical oncology : of- ficial journal of the American Society of Clinical Oncology. 1998;16(1):139-44. 13. Maenhout M, Peters M, van Vulpen M, Moerland MA, Meijer RP, van den Bosch M, et al. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Pa- tients With Radiorecurrent Prostate Cancer. Technology in cancer research & treatment. 2017;16(6):1194-201. 14. van Son MJ, Peters M, Moerland MA, La- gendijk JJW, Eppinga WSC, Shah TT, et al. MRI-guided ultrafocal salvage high- dose-rate brachytherapy for localized radiorecurrent prostate cancer: updated results of 50 patients. Int J Radiat Oncol Biol Phys. 2020.